Fact.MR, a market research and competitive intelligence provider: Urinary tract infection treatment market report forecasts 2.1% CAGR across the 2021-2031 assessment period.
Global UTI Infection Medicine Market Is Expected To Rise At 2.1% CAGR Through 2031.
“Increasing per capita consumption of antibiotics, rising incidence of UTI, and innovative drug delivery strategies are prompting healthcare providers to incorporate new treatment regimens for urinary tract infection,” says a Fact.MR analyst.
Fact.MR, a market research and competitive intelligence provider: Urinary tract infection treatment market report forecasts 2.1% CAGR across the 2021-2031 assessment period. As per the report by Fact.MR, a market research and competitive intelligence provider, the market is poised to be valued at around US$ 12.9 Bn by 2031. Growth is due to increasing prevalence of urinary tract infection, unhygienic lifestyles, antibiotic resistance, recurrence of complicated UTIs, and urinary catheterization. All these factors have significantly increased the number of hospital visits for UTI treatment per year.
The prevalence of complicated UTIs is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases.
For more insights into the Market, Get A Sample of this Report!
https://www.factmr.com/connectus/sample?flag=S&rep_id=7087
Urinary tract infection is amongst the most common bacterial infections that affect millions of people worldwide. Recurrent urinary tract infection is a major health issue in females across the globe. Increasing geriatric population is another factor that is expected to boost demand for UTI treatment as the elderly population is at high risk of contracting the same.
As per Medscape reported data in 2020, UTIs in women are very common; approximately 25-40% of women in the United States aged 20-40 years have had a UTI. UTIs account for over 6 million patient visits to physicians per year in the United States. Approximately 20% of those visits are to hospitals. It is estimated that 150 million UTIs occur yearly on a global basis.
Companies are expanding indications for existing antibiotic drugs and changing the administration route of these drugs to increase sales in terms of value and volume. It is easy for physicians to start intravenous therapy in hospitals if a drug is available in both forms: oral and intravenous. Hence, this different route of administration with different dosage is highly adopted by doctors, thereby providing lucrative opportunities to generate more revenue for market players.
Key Takeaways from Market Study
- By drug class, quinolones hold a high share of 45.7% in 2021, and the segment is set to expand at 2.5% CAGR over the forecast period of 2021 to 2031.
- By indication, uncomplicated UTI is valued at US$ 8 Bn in 2021, and is expected to increase to a value of US$ 9.7 Bn by 2031, indicating highest demand due to high prevalence of the disease.
- By distribution channel, retail pharmacies account for 55.8% market share.
- Europe held the largest share of 33.7% in the global urinary tract infection treatment market in 2021, due to major technological advancements and high percent of geriatric population who are more prone to UTIs.
For Comprehensive Insights Ask An Analyst Here
https://www.factmr.com/connectus/sample?flag=AE&rep_id=7087
Competitive Landscape
Key players such as Bayer AG and Pfizer, amongst others, are focusing on collaboration and research activities for approvals
- Bayer announced the initiation of the FIONA study, a multicenter, randomized, double-blind, placebo-controlled Phase III study, of finerenone for the treatment of pediatric patients with chronic kidney disease (CKD) and severely increased proteinuria (2021).
- Pfizer and LianBio announced a strategic collaboration to expand the development of novel therapeutics in Greater China (2020).
Similarly key developments of other companies such as GlaxoSmithKline Pharmaceuticals Ltd., Pfizer, Allergan Plc, Almirall SA, Bristol-Myers Squibb, and Merck & Co., Inc. have been tracked in the study by Fact.MR.
Rise in Prevalence of Urinary Tract Infection (UTI): A Key Driver
- Urinary tract infection (UTI) is one of the chronic diseases associated with the bladder, urethra, ureter, and kidneys. Over-reliance and high consumption of antibiotics are likely to increase antibiotic resistance in most UTI causing pathogens. This is projected to increase the prevalence of UTI in the near future.
- According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, in the U.S., around 60% women have symptomatic UTI during their lifetime, and around 10% women have one or more than one UTI episodes each year.
- Most urinary tract infections are caused due to the presence of E. coli. According to a study published in the International Journal of Contemporary Medical Research, approximately 37.4% of UTIs were caused due to E. coli
- Leading companies operating in the UTI treatment market are focusing on expanding production facilities and establishing long-term distribution contracts with major local distribution companies, to stay competitive among their peers in the urinary tract infection market.
Urinary Tract Infection Treatment Industry Survey by Category
- By Drug Class:
- Penicillin and Combinations
- Amoxicillin
- Amoxicillin and Clavulanate
- Potassium
- Others
- Quinolones
- Ciprofloxaxin
- Levofloxaxin
- Nalidixic acid
- Norfloxacin
- Others
- Cephalosporin
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin
- Aminoglycoside Antibiotics
- Amikacin
- Gentamicin
- Sulphonamides (Sulfamethoxazole +Trimethoprim)
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nirtofurans (Nitrofurantoin)
- Other
- Penicillin and Combinations
- By Indication:
- Complicated UTI
- Uncomplicated UTI
- By Distribution Channel:
- Hospital Pharmacies
- Gynecology and Urology Clinics
- Drug Stores
- Retail Pharmacies
- Online Drug Stores
- By Region:
- North America Urinary Tract Infection Treatment Market
- Latin America Urinary Tract Infection Treatment Market
- Europe Urinary Tract Infection Treatment Market
- East Asia Urinary Tract Infection Treatment Market
- South Asia Urinary Tract Infection Treatment Market
- Oceania Urinary Tract Infection Treatment Market
- Middle East and Africa (MEA) Urinary Tract Infection Treatment Market
Get Customization on this Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7087
More Valuable Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the urinary tract infection treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031.
The study divulges essential insights on the market on the basis of drug class (penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides (sulfamethoxazole + trimethoprim), azoles and amphotericin b, tetracycline (doxycycline), nitrofurans (nitrofurantoin), others), indication (complicated UTI, uncomplicated UTI), and by distribution channel (hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, online drug stores), across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa).
Fact.MR’s Domain Knowledge on Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Check out more studies related to Healthcare Industry, conducted by Fact.MR:
Medical Videoscopes Market - Medical Videoscopes Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
Medical Device Cleaning Market - Medical Device Cleaning Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
Americas Transplant Pathogen Monitoring Market - Americas Transplant Pathogen Monitoring Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2021 to 2031
Medical Oxygen Systems Market - Medical Oxygen Systems Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
Medical Laser Systems Market - Medical Laser Systems Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2021 to 2031
Hemostasis Diagnostics Market - Hemostasis Diagnostics Market Forecast Trend Analysis & Competition Tracking - Global Review 2021 to 2031
Poultry Diagnostics Market - Poultry Diagnostics Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
Oncology Molecular Diagnostic Market - Oncology Molecular Diagnostic Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2021 to 2031
Diagnostic Catheters Market - Diagnostic Catheters Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
Blood Cancer Diagnostics Market - Blood Cancer Diagnostics Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
Tel: +1 (628) 251-158